These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7944183)

  • 1. [Biological activities of heparins, other than their antithrombotic action].
    Vairel EG
    Ann Pharm Fr; 1994; 52(2):81-8. PubMed ID: 7944183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
    Brown JR; Kuter DJ
    Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of rat smooth muscle cell adhesion and proliferation by non-anticoagulant heparins.
    Kazi M; Lundmark K; Religa P; Gouda I; Larm O; Ray A; Swedenborg J; Hedin U
    J Cell Physiol; 2002 Dec; 193(3):365-72. PubMed ID: 12384988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S; Gastpar R
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic and thrombolytic activity of heparins in a rat model of laser-induced thrombosis.
    Krupiński K; Giedrojć J; Breddin HK; Bielawiec M
    Pol J Pharmacol; 1996; 48(3):345-50. PubMed ID: 9112675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
    Ammollo CT; Semeraro F; Semeraro N; Colucci M
    Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.
    Vignoli A; Marchetti M; Balducci D; Barbui T; Falanga A
    Haematologica; 2006 Feb; 91(2):207-14. PubMed ID: 16461305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High and low molecular weight heparins do not modify red blood cell aggregability in vitro.
    Martínez M; Vaya A; López-Camacho C; Coll-Sangrona E; Mira Y; Aznar J
    Clin Hemorheol Microcirc; 2000; 23(1):67-70. PubMed ID: 11214715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparins and angiogenesis.
    Norrby K
    APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraspecies differences in hemostatic venom activities of the South American rattlesnakes, Crotalus durissus cumanensis, as revealed by a range of protease inhibitors.
    Salazar AM; Aguilar I; Guerrero B; Girón ME; Lucena S; Sánchez EE; Rodríguez-Acosta A
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):525-30. PubMed ID: 18685436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of unfractionated and fractionated heparins on myeloperoxidase activity and interactions with endothelial cells: possible effects on the pathophysiology of equine laminitis.
    de la Rebière G; Franck T; Deby-Dupont G; Salciccia A; Grulke S; Péters F; Serteyn D
    Vet J; 2008 Oct; 178(1):62-9. PubMed ID: 17942351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparins--state-of-the-art and unsolved issues.
    Breddin HK
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S17-9. PubMed ID: 8180324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R; Umemura K; Hashimmoto H; Urano T
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of heparin and low molecular weight heparins on platelets.
    Vermylen JG
    Semin Thromb Hemost; 1993; 19 Suppl 1():20-1. PubMed ID: 8395723
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.